BILLERICA, Mass.--(BUSINESS WIRE)--Nirrin Technologies, a company developing analytical systems to transform analysis for bioprocessing operations, announced that Greg Crescenzi has joined the company as its Chief Executive Officer.

马萨诸塞州BILLERICA（BUSINESS WIRE）-开发分析系统以改变生物处理操作分析的公司Nirrin Technologies宣布Greg Crescenzi已加入该公司作为其首席执行官。

“Greg brings 30 years of strategic leadership in life science and biomanufacturing, and a long-standing history in commercializing industry-first tools and technologies,” said Matt Gunnison, CEO of Gamma Biosciences, a Nirrin strategic investor. “His track record of commercial successes and driving revenue growth sets a strong foundation for Nirrin as the company enters the commercialization phase for its high-precision tunable laser spectroscopy™ (HPTLS) platform.”.

Nirrin战略投资者Gamma Biosciences首席执行官Matt Gunnison说：“Greg在生命科学和生物制造领域拥有30年的战略领导力，并在商业化行业第一工具和技术方面拥有悠久的历史。”。“他的商业成功记录和推动收入增长为Nirrin奠定了坚实的基础，因为该公司因其高精度可调激光光谱进入商业化阶段™ （HPTLS）平台。”。

Greg most recently led Kytopen as its Chief Commercial Officer, where he effectively drove the commercial strategy to accelerate their non-viral gene delivery platform developed at MIT. Prior to that, Greg served as Enterprise Delivery Leader for the Cell & Gene Therapy business at Cytiva (formerly GE Healthcare Life Sciences), where he helped build out the Enterprise Solutions business, including delivery of the industry’s first flexible manufacturing platforms for biomanufacturing.

Greg最近领导Kytopen担任其首席商业官，在那里他有效地推动了商业战略，加速了麻省理工学院开发的非病毒基因传递平台。在此之前，Greg曾担任Cytiva（前身为GE Healthcare Life Sciences）的细胞和基因治疗业务的企业交付领导者，帮助建立企业解决方案业务，包括交付行业首个用于生物制造的灵活制造平台。

While at Cytiva he also served as Business Leader for Cell Culture Services, Xcellerex and Microcarriers, launching flagship products and quadrupling revenue..

在Cytiva，他还担任细胞培养服务，Xcellerex和微载体的业务领导者，推出旗舰产品和四倍收入。。

“Early evaluators of Nirrin’s HPTLS platform have validated its potential to completely disrupt how bioprocess scientists get excipient and protein data on their drug formulations. Typical time to answer can take weeks. Using our platform, early evaluators are getting actionable results in real time.

“Nirrin HPTLS平台的早期评估人员已经验证了其完全破坏生物过程科学家如何获得药物配方中赋形剂和蛋白质数据的潜力。典型的回答时间可能需要数周时间。使用我们的平台，早期评估人员正在实时获得可操作的结果。

I’m excited to see how our new STEP program partners utilize the HPTLS platform to speed time to answer in their own bioprocesses,” said Greg Crescenzi, CEO of Nirrin. “I am thrilled to partner with our founder and CTO, Bryan Hassell along with the entire Nirrin team to bring our breakthrough technologies to the biopharma market.”.

Nirrin首席执行官Greg Crescenzi说，我很高兴看到我们的新步骤计划合作伙伴如何利用HPTLS平台加快时间来回答他们自己的生物过程。“我很高兴与我们的创始人和首席技术官Bryan Hassell以及整个Nirrin团队合作，将我们的突破性技术带到生物制药市场。”。

Greg has also held business leadership, sales and marketing roles at key industry leaders including BD Biosciences, Pall Life Sciences and Millipore Corporation.

Greg还在BD Biosciences，Pall Life Sciences和Millipore Corporation等关键行业领导者担任业务领导，销售和营销角色。

About Nirrin Technologies

关于Nirrin技术

We are illuminating new insights in bioprocess operations for greater clarity and confident decision making. Our simple-to-use sophisticated analytical systems are powered by high-precision tunable laser spectroscopy™ (HPTLS) and poised to blaze new trails in near infrared (NIR) spectroscopy across the bioprocessing workflow.

为了更加清晰和自信的决策，我们正在阐明生物过程操作中的新见解。我们简单易用的复杂分析系统由高精度可调激光光谱提供动力™ （HPTLS），并准备在整个生物处理工作流程中开辟近红外（NIR）光谱的新途径。

Our team hails from Boston, MA and combines decades of industry experience with a passion for making life-changing medicines cheaper, easier, and faster to discover and manufacture..

我们的团队来自马萨诸塞州波士顿，凭借数十年的行业经验和热情，使改变生活的药物更便宜，更容易，更快速地发现和制造。。

For more information, visit nirrin.tech.

欲了解更多信息，请访问nirrin.tech。